中国当代儿科杂志Issue(8)：819-824,6.DOI:10.7499/j.issn.1008-8830.2015.08.012
伊马替尼治疗儿童Ph阳性急性淋巴细胞白血病的疗效和安全性
Efficacy and safety of imatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in children
摘要
Abstract
ObjectiveTo study the efficacy and safety of Chinese Childhood Leukemia Group ALL 2008 (CCLG-ALL2008) protocol combined with tyrosine kinase inhibitor(TKI,imatinib) for the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in children.MethodsThe clinical data of 53 patients aged less than 15 years when first diagnosed with Ph+ ALL between October 2008 and December 2013 were retrospectively analyzed. The patients were assigned to two groups: HR (n=26) and HR+TKI (n=27). The HR group was treated with CCLG-ALL2008 protocol (for high-risk patients). The HR+TKI group was treated with imatinib in combination with CCLG-ALL2008 protocol (for high-risk patients).ResultsThe complete remission rate and chemotherapy induction-related mortality rate in the TKI+HR and HR groups were 100% vs 75% and 0 vs 15%, respectively. The 3-year event-free survival (EFS) rate in the HR group was (6±5)%; the 5-year EFS rate of the TKI+HR group was (52±11)%. Compared with the HR group, the TKI+HR group had no increase in the toxic responses to chemotherapy and had a decrease in the infection rate during the induction period.ConclusionsApplication of imatinib significantly improves the clinical efficacy in children with Ph+ ALL and has good safety.关键词
伊马替尼/Ph染色体/急性淋巴细胞白血病/儿童Key words
Imatinib/Philadelphia chromosome/Acute lymphoblastic leukemia/Child引用本文复制引用
郭晔,刘晓明,戚本泉,邹尧,竺晓凡,刘天峰,阮敏,杨文钰,陈晓娟,张丽,王书春,刘芳,张家源..伊马替尼治疗儿童Ph阳性急性淋巴细胞白血病的疗效和安全性[J].中国当代儿科杂志,2015,(8):819-824,6.基金项目
国家科技支撑计划课题（2007BAI04B03）；天津市科技计划项目（12ZCDZSY18100）；国家科技重大专项子课题重大新药创制（2011ZX09302-007）。 （）
